Substituted pyrido[4,3-d]pyrimidines as Wee-1 inhibitors
The present invention relates to compounds of formula (I) that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.
1. A compound of Formula (I):
or a pharmaceutically acceptable salt or N-oxide thereof, wherein:
R 1 is a 2,6-dichlorophenyl group;
R 2 is a hydrogen atom;
R 3 is a group represented by the formula (c):
wherein Z is a methine group;
R 3a is a nitrogen-containing heterocyclyl group; and
R 3b is a C 1 -C 6 alkyl group, a C 2 -C 6 alkenyl group, a C 2 -C 6 alkynyl group, or a C 1 -C 6 alkoxy group;
wherein the C 1 -C 6 alkyl group, the C 2 -C 6 alkenyl group, the C 2 -C 6 alkynyl group, or the C 1 -C 6 alkoxy group is optionally substituted with one or more substituents selected from alkyl, aralkyl, alkenyl, alkynyl, halo, cyano, amino, amido, alkylamino, arylamino, carbocyclyl, cycloalkyl, cycloalkenyl, aryl, nitro, thio, alkanoyl, hydroxy, aryloxy, alkoxy, alkylthio, arylthio, aralkyloxy, aralkylthio, carboxy, alkoxycarbonyl, oxo, alkylsulfonyl and arylsulfonyl.
2. The compound of claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein R 3 is a group represented by the formula (e):
.
3. The compound of claim 2 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein
R 3b is a methoxy group or a C 1 -C 2 alkyl group, wherein the C 1 -C 2 alkyl group is optionally substituted with a substituent selected from the group consisting of hydroxy and amino.
4. The compound of claim 3 , wherein R 3b is a methoxy group.
5. The compound of claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, wherein the compound is selected from the group consisting of:
(7) 6- (2,6-dichlorophenyl)-2-((3-methyl-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one;
(13) 6-(2,6-dichlorophenyl)-2-((3-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one;
(18) 6-(2,6-dichlorophenyl)-2-((3-(hydroxymethyl)-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one; and
(20) 6-(2,6-dichlorophenyl)-2-((3-((methylamino)methyl)-4-morpholinophenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one.
6. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt or N-oxide thereof, and at least one pharmaceutically acceptable excipient.
7. The pharmaceutical composition of claim 6 , further comprising one or more further pharmaceutically active agents.
8. A method of modulating Wee-1 kinase activity in a human or animal patient in need thereof, comprising administering to the patient an effective amount of a compound of claim 1 .
9. The method of claim 8 , wherein the human or animal patient suffers from cancer.
10. A compound selected from the group consisting of:
(7) 6-(2,6-dichlorophenyl)-2-((3-methyl-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one; and
(13) 6-(2,6-dichlorophenyl)-2-((3-methoxy-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one.
11. A compound selected from the group consisting of:
(8) 6-(2,6-dichlorophenyl)-2-((3-(hydroxymethyl)-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one;
(12) 6-(2,6-dichlorophenyl)-2-((3-methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one;
(14) 6-(2,6-dichlorophenyl)-8-(3-hydroxyprop-1-yn-1-yl)-2-((3-methyl-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one;
(27) 6-(2,6-dichlorophenyl)-2-((3-chloro-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one; and
(29) 6-(2,6-dichlorophenyl)-2-((3-fluoro-4-(piperazin-1-yl)phenyl)amino)pyrido[4,3-d]pyrimidin-5(6H)-one.